These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Modulation of BAG-1 expression alters the sensitivity of breast cancer cells to tamoxifen. Liu H; Lu S; Gu L; Gao Y; Wang T; Zhao J; Rao J; Chen J; Hao X; Tang SC Cell Physiol Biochem; 2014; 33(2):365-74. PubMed ID: 24557447 [TBL] [Abstract][Full Text] [Related]
23. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302 [TBL] [Abstract][Full Text] [Related]
24. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer. Jia Y; Zhou J; Luo X; Chen M; Chen Y; Wang J; Xiong H; Ying X; Hu W; Zhao W; Deng W; Wang L Cell Signal; 2018 Jan; 42():165-175. PubMed ID: 28988130 [TBL] [Abstract][Full Text] [Related]
25. Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells. Lin JH; Tu SH; Chen LC; Huang CC; Chang HL; Cheng TC; Chang HW; Wu CH; Wu HC; Ho YS Breast Cancer Res Treat; 2018 Nov; 172(1):45-59. PubMed ID: 30054830 [TBL] [Abstract][Full Text] [Related]
26. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression. Shah N; Jin K; Cruz LA; Park S; Sadik H; Cho S; Goswami CP; Nakshatri H; Gupta R; Chang HY; Zhang Z; Cimino-Mathews A; Cope L; Umbricht C; Sukumar S Cancer Res; 2013 Sep; 73(17):5449-58. PubMed ID: 23832664 [TBL] [Abstract][Full Text] [Related]
27. Up-regulation of HOXB cluster genes are epigenetically regulated in tamoxifen-resistant MCF7 breast cancer cells. Yang S; Lee JY; Hur H; Oh JH; Kim MH BMB Rep; 2018 Sep; 51(9):450-455. PubMed ID: 29804556 [TBL] [Abstract][Full Text] [Related]
28. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity. Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866 [TBL] [Abstract][Full Text] [Related]
29. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer. Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905 [TBL] [Abstract][Full Text] [Related]
30. Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer. Liu B; Wang T; Wang H; Zhang L; Xu F; Fang R; Li L; Cai X; Wu Y; Zhang W; Ye L J Hematol Oncol; 2018 Feb; 11(1):26. PubMed ID: 29471853 [TBL] [Abstract][Full Text] [Related]
31. Solid lipid nanoparticles: Reversal of tamoxifen resistance in breast cancer. Guney Eskiler G; Cecener G; Dikmen G; Egeli U; Tunca B Eur J Pharm Sci; 2018 Jul; 120():73-88. PubMed ID: 29719240 [TBL] [Abstract][Full Text] [Related]
32. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells. Yang JW; Kim MR; Kim HG; Kim SK; Jeong HG; Kang KW Arch Pharm Res; 2008 Mar; 31(3):350-6. PubMed ID: 18409049 [TBL] [Abstract][Full Text] [Related]
33. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells. Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334 [TBL] [Abstract][Full Text] [Related]
34. Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts. Cottu P; Bièche I; Assayag F; El Botty R; Chateau-Joubert S; Thuleau A; Bagarre T; Albaud B; Rapinat A; Gentien D; de la Grange P; Sibut V; Vacher S; Hatem R; Servely JL; Fontaine JJ; Decaudin D; Pierga JY; Roman-Roman S; Marangoni E Clin Cancer Res; 2014 Aug; 20(16):4314-25. PubMed ID: 24947930 [TBL] [Abstract][Full Text] [Related]
35. Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells. Phuong NT; Kim SK; Im JH; Yang JW; Choi MC; Lim SC; Lee KY; Kim YM; Yoon JH; Kang KW Oncotarget; 2016 Mar; 7(12):13902-16. PubMed ID: 26418898 [TBL] [Abstract][Full Text] [Related]
36. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22. Li J; Lu M; Jin J; Lu X; Xu T; Jin S Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449 [TBL] [Abstract][Full Text] [Related]
37. Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells. Gao P; Wang X; Jin Y; Hu W; Duan Y; Shi A; Du Y; Song D; Yang M; Li S; Han B; Zhao G; Zhang H; Fan Z; Miao QR Breast Cancer Res; 2018 Sep; 20(1):112. PubMed ID: 30208932 [TBL] [Abstract][Full Text] [Related]
38. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells. Kim SS; Lee MH; Lee MO Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900 [TBL] [Abstract][Full Text] [Related]
39. SOX4-mediated FBW7 transcriptional upregulation confers Tamoxifen resistance in ER+ breast cancers via GATA3 downregulation. Sharma A; Thacker G; Mishra M; Singh AK; Upadhyay V; Sanyal S; Trivedi AK Life Sci; 2022 Aug; 303():120682. PubMed ID: 35662647 [TBL] [Abstract][Full Text] [Related]
40. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]